CMT-3, a chemically modified tetracycline, inhibits pony metastases and delays the development of paraplegia in a rat model of prostate cancer

Annals of the New York Academy of Sciences

Volumn 878, Issue , 1999, Pages 678-682

  Selzer, Marie G ^a   Zhu, Baoqian ^a   Block, Norman L ^a   Lokeshwar, Bal L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; MATRIX METALLOPROTEINASE INHIBITOR; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE METASTASIS; CANCER MODEL; CONFERENCE PAPER; CONTROLLED STUDY; MALE; METASTASIS INHIBITION; NONHUMAN; ORAL DRUG ADMINISTRATION; PARAPLEGIA; PROSTATE CANCER; RAT;

ANIMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0032837305     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb07760.x     Document Type: Conference Paper

References (12)

1. 1. Landis, S.H., T. Murray, S. Bolden & P.A., Wingo. 1998. Cancer statistics, 1998. CA Cancer J. Clinicians 48(1): 6-29.
2. 2. Jacobs, S.C. 1983. Spread of prostate cancer to bone. Urology 21: 337-344.
3. 3. Glotzman, D. 1997. Mechanisms of the development of osteoblastic metastases. Cancer 80: 1581-1587.
4. 4. Quax, P.H.A., A.C.W. Bart, J.A. Schalken & J.H. Verheijen. 1997. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. Prostate 32: 196-204.
5. 5. Stetler-Stevenson, W.G., S. Aznavoorian & L.A. Liotta. 1993. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Ann. Rev. Cell Biol. 9: 541-573.
6. 6. Mahler, C. & L. Denis. 1992. Management of relapsing disease in prostate cancer. Cancer 70: 329-334.
7. 7. Lokeshwar, B.L., M.G. Selzer, N.L. Block & Z. Gunja-Smith. 1993. Secretion of matrix metalloproteinases and their inhibitors (TIMPs) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res. 53: 4493-4498.
8. 8. Sasaki, T., N.S. Ramamurthy & L.M. Golub. 1994. Bone cells and matrix bind chemically modified non-antimicrobial tetracycline. Bone 15: 373-375.
9. 9. Geldof, A.A. & B.R. Rao. 1990. Prostate tumor (R3327) skeletal metastasis. Prostate 16: 279-290.
10. 10. Lokeshwar, B.L., M.G. Selzer, N.L. Block & L.M. Golub. 1997. Inhibition of tumor growth and metastasis by a non-antimicrobial tetracycline analogue in a prostate cancer model. Proc. Amer. Assoc. Cancer Res. 38: 2868a.
11. 11. Lokeshwar, B., S. DudAK, M. Selzer, N. Block & L. Golub. 1996. Novel therapies for metastatic prostate cancer: chemically modified tetracycline. In Therapeutic strategies in Molecular Medicine, Miami Biotechnology Short Report 7: Advances in Gene Technology. W.J. Whelan et al. Eds. Oxford University Press. London.
12. 12. Lokeshwar, B.L., M.G. Selzer, N.L. Block & L. M. Golub. 1997. COL-3: a modified non-antimicrobial tetracycline decreases prostate tumor growth and metastasis. J. Dent. Res. 76: 3481A.